Lupin has acquired 100 per cent equity stake in Laboratorios Grin, S.A. De C.V., Mexico, subject to certain closing conditions, for an unspecified amount. The acquisition marks Lupin’s entry into the high-growth Mexican and the larger Latin American pharmaceuticals market. “We see a lot of synergies in this acquisition and plan to bring our ophthalmic pipeline to build the Grin business as well as leverage their commercial presence to enter other promising therapy segments,” Vinita Gupta, Chief Executive Officer, Lupin, said.
